Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties by Zanchi, Anne et al.
ht
tp
://
do
c.
re
ro
.c
h
Telmisartan prevents the glitazone-induced weight gain without interfering
with its insulin-sensitizing properties
Anne Zanchi,1 Abdul G. Dulloo,2 Christine Perregaux,1 Jean-Pierre Montani,2 and Michel Burnier1
1Division of Nephrology and Department of Medicine, Centre Hospitalier Universitaire Vaudois and University
of Lausanne, Lausanne; and 2Division of Physiology, University of Fribourg, Fribourg, Switzerland
Glitazones are peroxisome prolif-
erator-activated receptor (PPAR)- agonists with powerful insulin-
sensitizing properties. They promote the development of metaboli-
cally active adipocytes that can lead to a substantial gain in fat mass.
Telmisartan is an ANG II type 1 receptor antagonist with partial
PPAR- agonistic properties. Recently, telmisartan has been reported
to prevent weight gain and improve insulin sensitivity in diet-induced
obese rodents. The goal of this study was to examine the inﬂuence of
telmisartan on pioglitazone-induced weight gain and insulin-sensitiz-
ing properties in the following two models of insulin resistance: a
nongenetic model (high-fat-fed Sprague Dawley rats) and the genet-
ically obese fa/fa Zucker rat. After a 4-wk treatment, the pioglitazone-
induced increase in fat mass was modest in the Sprague Dawley rats
and severe in the Zucker rats. In both models, these effects were
substantially decreased by concomitant treatment with telmisartan.
The effects of telmisartan on body weight and fat mass in the Zucker
rats were abolished by pair feeding, suggesting that it is the result of
a decrease in food intake. Telmisartan did not interfere with the
insulin-sensitizing properties of pioglitazone. This study demonstrates
that telmisartan attenuates the glitazone-induced increase in fat mass
without interfering with its insulin-sensitizing properties.
glitazones; fat; angiotensin II receptor blocker
GLITAZONES are peroxisome proliferator-activated receptor
(PPAR)- agonists currently used in the treatment of type 2
diabetes (15). These drugs are the most powerful insulin
sensitizers available in clinical practice. Their actions are
predominantly driven by their inﬂuence on adipocyte metabo-
lism. However, because these drugs promote adipogenesis,
their uses are often associated with weight gain mainly through
an increase in fat mass (6). This side effect may be the reason
why some patients stop the drug. The increase in fat mass has
been correlated to the efﬁcacy of the drug, since “responders”
are among those who show the greatest weight gain (3). Thus
the differentiation of preadipocytes to insulin-sensitive adipo-
cytes is a major contributor to the improvement of insulin
resistance with glitazones.
Although clinical studies were not able to demonstrate any
increase in food intake or decrease in energy expenditure (13),
animal studies clearly show that glitazone treatment is associ-
ated with an increase in food intake and feed efﬁciency (7).
The mechanisms involved are not known but could be related
to the inﬂuence of glitazones on neuroendocrine mediators
involved in food intake.
Blockers of the renin-angiotensin system have been shown
to confer cardiac and renal protection and to lower the inci-
dence of new cases of diabetes in high-risk patients (2).
Telmisartan is an ANG II type 1 receptor antagonist that has
partial PPAR- agonistic properties (1, 12). For comparison,
the EC50 for PPAR- agonistic effects of telmisartan is of 4.5
mol/l (1), and the IC50 for ANG II receptor blockade is of 9.2
nmol/l in rats (8). Telmisartan activates PPAR- in cell-based
transient transfection assays by 21–50% of the maximum level
obtained with pioglitazone. Telmisartan has been reported to
prevent weight gain and to improve insulin sensitivity in
diet-induced obese mice (11) and to attenuate weight gain
induced by an energy-dense diet (rich fructose and lard) in
Sprague Dawley rats (14). Whether telmisartan, a “partial”
PPAR- agonist, will interfere with the insulin-sensitizing
properties of a “full” PPAR- agonist like pioglitazone is not
known. Furthermore, whether telmisartan is able to prevent the
weight gain induced by a glitazone in models of insulin
resistance, as found previously in models of diet-induced
obesity, has not been investigated so far.
The goal of this study was to examine the inﬂuence of
telmisartan on weight gain induced by pioglitazone in the
following two models of insulin resistance: the Sprague Daw-
ley rat fed a high-fat diet rich in lard (a nongenetic model of
insulin resistance) and the obese Zucker rat (a genetic model of
insulin resistance) known to gain a large amount of body fat
when treated with a glitazone (18).
RESEARCH DESIGN AND METHODS
Sprague Dawley rats fed ad libitum. Male Sprague Dawley rats,
age 8 wk were caged singly in a temperature-controlled room (22 
1°C) with a 12:12-h light-dark cycle. They had ad libitum access to
water and to a high-fat diet (rich in lard) consisting (by energy) of
45% fat, 34% carbohydrates, and 21% protein (diet 2126; Provimi
Kliba, Cossonay, Switzerland). Control (n  6), pioglitazone (20
mg kg1 day1, n  6), telmisartan (5 mg kg1 day1, n  6), and
pioglitazone and telmisartan (n  6) were administered for 4 wk.
Randomization to each group was chosen to have identical average
weights in all groups at baseline.
Pioglitazone was incorporated in the diet (0.24 g/kg) and telmis-
artan was added to the drinking water at a concentration of 0.025–0.1
g/l to match an average intake of 5 mg kg1 day1. At the end of the
treatment period, the animals were killed by decapitation for the
determination of body composition as described below. Arterial blood
was collected for biochemical analysis.
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Obese Zucker rats fed ad libitum. Male obese fa/fa Zucker rats (Iffa
Credo, Lyon, France), aged 8 wk, were fed ad libitum (regular rat
chow) with vehicle, pioglitazone, telmisartan, and pioglitazone and
telmisartan (n  12–14 in each group) at similar doses as above.
Randomization to each group was chosen to have average identical
weights in all groups at baseline. They had ad libitum access to water and
to a standard chow diet for 4 wk [consisting by energy: 52.8% carbohy-
drates, 9.2% fat, 38% protein (diet 3200; Kliba)]. A subgroup of rats (n
6 in each group) was caged singly for accurate food intake and weight
control. Another subgroup of animals (n  6–8 in each group) under-
went an intravenous glucose tolerance test (IVGTT) at the end of the
4-wk treatment period. They were anesthetized with halothane and had
their right femoral artery and vein canulated with a PE-50 catheter. The
animals were then returned to their cage. On the following day after an
overnight fast, they were placed in a plastic tube for partial restriction of
their movements. Intra-arterial blood pressure measurements were per-
formed after 1 h rest (17). An IVGTT was then performed with a bolus
injection of 0.5 g/kg glucose and the determination of whole blood
glucose and plasma insulin at 0, 4, 7, 10, 15, and 30 min. Insulin
resistance index at baseline was assessed by HOMA-IR (9).
Pair-fed obese Zucker rats. Two groups of male obese fa/fa Zucker
rats, aged 8 wk, caged singly in a temperature-controlled room, were
pair fed on standard chow diet for 4 wk and were treated with
pioglitazone (n  10) or pioglitazone and telmisartan (n  10).
Randomization to each group was chosen to have identical average
weights at baseline. To prevent food spillage, the chow was provided
in food pots and in the form of a paste consisting of powdered chow
mixed with water (1:1 by weight). Food intake was increased pro-
gressively with time to ensure that all groups consumed exactly the
same amount of food. At the end of the treatment period, the animals
were killed by decapitation for the determination of body composition
as described below.
Procedures used in this study were in accordance with principles of
animal care and according to the institutional guidelines. The protocol
was reviewed and approved by an independent ethical committee for
animal research.
Determination of body composition. After death by decapitation,
blood was collected; the skull, thorax, and abdominal cavity were
incised; and the gut was cleaned of undigested food. The whole
carcasses were dried to a constant weight in an oven maintained at
70°C and subsequently homogenized. Triplicate samples of the ho-
mogenized carcass were analyzed for energy content by bomb calo-
rimetry (10) and for fat content by the Soxhlet extraction method (5).
Total body water was calculated from the difference between body
weight and carcass dry weight, whereas fat-free-dry mass (a proxy for
body protein mass) was calculated from the difference between
carcass dry weight and carcass fat (4).
Biochemical parameters. Blood glucose levels were determined
with the Glucometer Elite XL (Bayer). Plasma insulin was determined
by RIA (Insulin-RIA; Pharmacia, Du¨bendorf, Switzerland).
Statistical analysis. Data are expressed as means  SE. The
statistical signiﬁcance of differences between the treatment groups
was evaluated by ANOVA (Minitab) followed by Fisher’s test for
multiple comparisons. A level of P 0.05 was considered statistically
signiﬁcant.
RESULTS
Sprague Dawley rats fed ad libitum. Gain in body weight
was signiﬁcantly less in telmisartan-treated rats than in controls
or in pioglitazone-treated rats [ﬁnal body weight (g, means 
SE): control, 428  7; pioglitazone, 443  8; telmisartan,
401  6; pioglitazone-telmisartan, 409  14, P  0.01 by
Fig. 1. Mean body weight, abdominal fat,
and total body fat (g) of control or telmisar-
tan-treated rats (A) and pioglitazone- or pio-
glitazone- and telmisartan-treated rats (B).
Shown are means  SE.
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ANOVA; Fig. 1]. Abdominal fat and total body fat increased
with pioglitazone and decreased with telmisartan (Fig. 1).
Overall, telmisartan added to pioglitazone abolished the in-
crease in body weight and in total body fat because of piogli-
tazone. During the course of the study, food intake tended to be
periodically higher with pioglitazone and periodically lower
with telmisartan, with large interanimal variability across time,
resulting in no statistical difference for food intake integrated
over the 4-wk period [total food intake (g): control, 672.5 
9.2; pioglitazone, 706.3  20.9; telmisartan, 660.4  14.9;
pioglitazone-telmisartan, 684.8  20.7, P  0.3]. Although
total food intake over the 4-wk period did not statistically differ
between groups, we could demonstrate a strong correlation
between the total food intake and total body fat (r2  51.4%,
P  0.002). Total body water and fat-free dry mass did not
differ between groups. Adding telmisartan to water was not
associated with a decrease in water intake.
Insulin levels and the HOMA-IR score were signiﬁcantly
decreased in pioglitazone and pioglitazone-telmisartan treated
rats as follows: insulin (ng/ml, means  SE): control 1.77 
0.19, pioglitazone 0.58  0.13, telmisartan 2.04  0.21,
pioglitazone-telmisartan 0.50  0.06, P  0.001; HOMA-IR
score: control 17.6  2.0, pioglitazone 5.8  1.4, telmisartan
20.3  2.1, pioglitazone-telmisartan 4.6  0.6, P  0.001.
Glucose levels did not differ between groups. Telmisartan
treatment alone had no signiﬁcant effect on these parameters.
Obese Zucker rats fed ad libitum: Weight gain, IVGTT,
intra-arterial blood pressure measurement. Pioglitazone treat-
ment was associated with a progressive and substantial gain in
body weight compared with control rats (P signiﬁcant from
day 4; Fig. 2). Telmisartan treatment signiﬁcantly attenuated
the gain in weight induced by pioglitazone (P signiﬁcant from
day 16). Telmisartan treatment alone attenuated the gain in
weight but not signiﬁcantly. Telmisartan alone had no impact
on food intake but with time decreased the hyperphagic effect
of pioglitazone treatment. This effect increased week by week
to a signiﬁcant level. The total food intake (g) at week 4 was as
follows (in g): control 685.4  29.2, pioglitazone 930  30.5,
telmisartan 676.8  21.2, pioglitazone-telmisartan 846.4 
18.1, P  0.001. Total weight gain was strongly correlated to
the cumulative food intake (r2  92.9%, P  0.001; Fig. 2).
Adding telmisartan to water was not associated with a decrease
in water intake.
Plasma insulin levels, the HOMA-IR index, and the insulin-
glucose response during the IVGTT were signiﬁcantly im-
proved with pioglitazone (Fig. 3). Telmisartan treatment alone
slightly decreased (but nonsigniﬁcantly) the basal plasma in-
sulin and glucose levels (the HOMA-IR) and also resulted in a
signiﬁcant reduction in the plasma glucose levels at 0, 7, 30
min of the IVGTT. Plasma insulin levels were, however,
signiﬁcantly higher than controls at 10 min of the IVGTT. In
spite of this, the insulin-sensitizing properties of pioglitazone
were not affected by telmisartan during the IVGTT.
Intra-arterial mean blood pressure decreased signiﬁcantly
with pioglitazone and telmisartan as follows: control 115  2
mmHg, pioglitazone 92  2 mmHg, telmisartan 89  3
mmHg, pioglitazone-telmisartan 83  2 mmHg (P  0.001).
Pair-fed obese Zucker rats: Pioglitazone vs. pioglitazone-
telmisartan. The gain in body weight was not different between
the pioglitazone-treated group and the pioglitazone- and tel-
misartan-treated group (Fig. 4). Even when the study was
extended to 36 days, there was no difference in weight between
groups (means  SE: pioglitazone vs. pioglitazone-telmisar-
tan: 539  4 vs. 530  5 g, respectively) nor was there a
difference in total abdominal fat (27.5  0.7 vs. 26.2  0.7 g,
respectively) or in whole body fat (316  6 vs. 320  4 g,
respectively). Telmisartan signiﬁcantly decreased total water
content (223 5 vs. 209 4 g, P 0.05) and the heart weight
(1.21  0.01 vs. 1.11  0.01 g, P  0.001) and had no
signiﬁcant effect on the fat-free dry mass or on the weight of
other organs/tissues (kidney, liver).
DISCUSSION
The main ﬁndings of the study presented here can be
summarized as follows. 1) The excess gain in body weight and
in body fat associated with pioglitazone treatment is modest in
a nongenetic (dietary) model and severe in a genetic (defective
leptin receptor) model of insulin resistance. 2) In both models,
these effects of pioglitazone on excess weight and body fat
Fig. 2. Weight gain (g) and correlation with cumulative food intake (g) in
obese Zucker rats fed ad libitum. *P  0.05 vs. pioglitazone- and telmisartan-
treated rats.
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gains are attenuated by concomitant treatment with telmisartan.
3) This anti-obesity effect of telmisartan in the obese Zucker
rats can be attributed to a decrease in food intake, since
cumulative food intake was signiﬁcantly decreased in rats fed
ad libitum, and weight differences were abolished by pair-
feeding. Furthermore, telmisartan treatment resulted in lower
mean food intake in the Sprague Dawley rats, although no
statistical differences could be observed because of the large
intragroup variability in total food intake. However, our ﬁnd-
ings of a strong positive relation between food intake and
weight gain in both models is consistent with an important role
for reduced food intake in the antiobesity effect of telmisartan.
4) In spite of the described PPAR- properties of telmisartan,
our data suggest that it does not improve the insulin-glucose
response to an intravenous glucose bolus in the insulin-resis-
tant obese Zucker rat. However, they also suggest that telmis-
artan does not interfere with the powerful insulin-sensitizing
properties of pioglitazone in this model.
Telmisartan is an ANG II receptor blocker that has PPAR-
properties in vitro independent from its angiotensin type 1
receptor blocking properties. In vivo, telmisartan has been
shown to prevent weight gain and to improve insulin sensitivity
in a mouse model of diet-induced obesity (11). In Sprague
Dawley rats, in which weight gain was induced by a high-
fructose high-lard diet, telmisartan has also been reported to
prevent weight gain, to reduce the accumulation of visceral fat,
and to decrease adipocyte size and hepatic triglyceride content
(14). In this latter study, the food intake (in absolute terms) was
lower in telmisartan-treated rats, and energy expenditure (ex-
pressed per unit body wt) was increased. Although the length
of our study was much shorter (4 wk vs. 12 wk) we were able
to reproduce the favorable effects of telmisartan on weight gain
and accumulation of fat in this model. Furthermore, the orig-
inal ﬁnding in our study is that telmisartan is also able to
completely abolish the excess weight gain and fat accumula-
tion induced by pioglitazone treatment in Sprague Dawley rats
fed a high-fat diet.
However, because the weight gain induced by pioglitazone
is modest, we extended these studies to an insulin-resistant
model known to dramatically increase its body weight with a
glitazone. Telmisartan alone had a very moderate effect on
body weight in this model but substantially prevented the
increase in body weight induced by pioglitazone and decreased
food intake. To investigate an effect of telmisartan on food
intake, we clamped the food intake by pair-feeding these rats.
The results demonstrate clearly that, when food intake is the
same, gain in body weight is no longer different between
pioglitazone- and pioglitazone/telmisartan-treated rats. These
data therefore suggest that, in the obese Zucker rat model of
insulin resistance, telmisartan strongly attenuates the weight
gain induced by pioglitazone through an inhibition of food
intake and not through increases in energy expenditure. Be-
cause adding telmisartan to water was not associated with a
Fig. 4. Mean body weight (g) of pair-fed obese Zucker rats.
Fig. 3. Intravenous glucose tolerance test and HOMA insulin resistance index
in obese Zucker rats. Changes in plasma glucose (mmol/l) and insulin (ng/ml)
levels after an iv bolus of 0.5 g/kg glucose. *P  0.05 vs. control.
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decrease in water intake, a taste aversion of telmisartan in
water is an unlikely mechanism for the decreased food intake
in telmisartan-treated rats.
Telmisartan treatment did not have a robust effect on the
insulin-glucose response in the obese Zucker rats in contrast to
earlier ﬁndings in the Sprague Dawley rat (1). Nevertheless,
and importantly, it did not interfere with the insulin-sensitizing
properties of pioglitazone in rats fed ad libitum as may have
been feared because of its partial (agonist/antagonist) PPAR-
properties (11). Glucose homeostasis was, however, not stud-
ied in pair-fed Zucker rats; thus, these data do not inform on
the interaction of telmisartan on the insulin-sensitizing prop-
erties of pioglitazone when body weight remains the same.
Weight gain resulting from glitazones is sometimes related
to ﬂuid retention due to the activation of renal sodium retention
(17). Through its ANG II antagonistic properties, telmisartan
could prevent this effect. Indeed, when telmisartan was admin-
istered together with pioglitazone, the total water content of the
rats showed a tendency to be lower in the Zucker model.
However, this small difference is body water does not explain
the large differences in body weight found when these rats are
fed ad libitum.
Glitazones are PPAR- agonists with powerful insulin-
sensitizing properties. Their main actions are related to the
development of metabolically active insulin-sensitive adipo-
cytes whose accumulation can, however, lead to a substantial
gain in “healthy” fat mass. The fact that telmisartan is able to
prevent the glitazone-induced weight gain, without interfering
with its insulin-sensitizing properties will motivate future stud-
ies, particularly at the neuroendocrine level. Although different
mechanisms may be involved, a decrease in food intake with
telmisartan is the major contributing mechanism in both animal
models treated with pioglitazone. Further studies are required
to determine if this favorable interaction with pioglitazone is
speciﬁc to telmisartan or if it also occurs with other ANG II
receptor blockers. In the meantime, since an ANG II receptor
antagonist together with a glitazone are often prescribed to
diabetic patients, the association of pioglitazone and telmisar-
tan is an attractive combination particularly with respect to
weight control.
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